Explore 3 Stock Ideas & Industry Insights Download Free Report

Kalkine Real Estate Report

HealthCo Healthcare & Wellness REIT

Nov 19, 2024

  • HCW:ASX
  • Investment Type
    Small-Cap
  • Risk Level
  • Action
  • Rec. Price (AU$)

Company Overview: HealthCo Healthcare & Wellness REIT (ASX: HCW) is an ASX-listed Real Estate Investment Trust specializing in healthcare and wellness property assets. Its aim is to offer investors exposure to a diversified portfolio driven by major healthcare sector trends, focusing on delivering stable and growing distributions, long-term capital appreciation, and positive environmental and social outcomes. Kalkine’s Real Estate Report covers the Investment Highlights, Management Insights, Key Financial Metrics, Risks, Technical Analysis along with the Valuation, Target Price, and Recommendation on the stock.  

The top 10 shareholders together form ~41.20% of the total shareholding. Di Pilla (David) held the maximum number of shares with a percentage holding of 22.4%, followed by The Vanguard Group, Inc. holding 7.52%, as also highlighted in the chart below:

The companys gross margin stood at 87.3% in FY24, as compared to 79.2% reported in the year-ago period. The picture below depicts the operating margin and current ratio trend:

2.3: Historical Financial Highlights

The stock price went down by ~5.39% in last three months, and over the last nine months, stock prices went down by ~14.93%. The stock has a 52-week low and 52-week high of AUD 1.045 and AUD 1.550, respectively, and is currently trading below its mid-range of the 52-week-high-low levels. HCW was last covered in a report dated ’30 September 2024’.





Markets are trading in a highly volatile zone currently due to certain macro-economic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

 

Note 1: Past performance is neither an indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is 19 November 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.
Note 4: Dividend Yield may vary as per the stock price movement.  

Technical Indicators Defined: - 

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.

Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.


Disclaimer-

Disclaimer This report has been issued by Kalkine New Zealand Limited (FSP691351) (NZBN:9429047678101) (“Kalkine”). Kalkine is a Financial Advice Provider (“FAP”) and is authorised by a Class 1 Financial Advice Provider Licence issued by Financial Markets Authority (“FMA”) to provide financial advice. Kalkine provides only general financial advice through its research reports following a person becoming a member. The reports contain buy/sell/hold and other recommendations in relation to equity securities, managed funds and other managed investment schemes and other financial advice products. The recommendations and opinions in this report and on Kalkine website do not take into account any of your investment objectives, financial situation or needs. Before you make a decision about whether to acquire a financial product, you should obtain the Product Disclosure Statement from the product issuer. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. If you act on the advice in the research reports, you may have to pay fees, expenses or other amounts (but not to Kalkine). Further information about the complaints and dispute resolution process, as well as information about Kalkine’s duties are available on Kalkine’s website. Please read our Financial Advice Provider (FAP) disclosure statement and Complaints Handling Guide, which are available on the website.

Past performance is not a reliable indicator of future performance.